- Details
- Zachary Klaassen hosts Sandip Prasad to discuss the ENVISION trial investigating UGN-102 for primary chemo ablation of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Dr. Prasad discusses this approach that treats tumors directly rather than using traditional TURBT followed by adjuvant therapy. The trial demonstrated a 79.6% complete response rate at three months, and amo...
|
- Details
- Ashish Kamat is joined by Dan Isaac to discuss findings from a proof-of-principle study on circulating tumor DNA (ctDNA) in high-risk non-muscle invasive bladder cancer patients. Dr. Isaac shares results from a small cohort study that detected positive ctDNA in two of ten high-risk patients during surveillance. Both patients had normal clinical findings at the time of ctDNA detection but subsequen...
|
- Details
- Ashish Kamat is joined by Alexander Wyatt to discuss circulating tumor DNA technology. Dr. Wyatt breaks down the fundamentals of cell-free DNA and how ctDNA represents the tumor-derived portion of these fragments in the bloodstream. He distinguishes between two critical approaches: detection tests that identify cancer presence (vital in early disease) and characterization tests that analyze specif...
|
- Details
- Koral Shah joins Ashish Kamat to discuss research on worldwide disparities in bladder cancer clinical trials. Examining 539 trials across 63 countries from 2019-2024, Dr. Shah reveals stark inequities based on World Bank income classifications. While high-income countries host 79% of trials (half in the US alone), non-high-income countries bear a disproportionate mortality burden. Her analysis fou...
|
- Details
- Sandeep (Bobby) Reddy discusses ResQ132A, a trial targeting intermediate-risk bladder cancer. Dr. Reddy recaps QUILT 3.032, which led to N-803's approval in BCG-unresponsive disease with a 62% complete response rate and durable outcomes. The ResQ132A trial study compares BCG plus N-803 versus gemcitabine plus N-803 in intermediate-risk patients, addressing an unmet need where patients typically ex...
|
- Details
- Ashish Kamat is joined by Michael O'Donnell to discuss gene expression signatures and immune infiltration in response to intravesical gemcitabine/docetaxel versus BCG in high-risk non-muscle-invasive bladder cancer. Dr. O'Donnell shares findings from a collaborative four-institution study exploring treatment alternatives amid BCG shortages. While genomic subtypes showed no correlation with outcome...
|
- Details
- Sam Chang hosts Alan Tan to discuss molecular profiling in bladder cancer, focusing on circulating tumor DNA (ctDNA) and urinary tract DNA (utDNA) applications. Dr. Tan explains how these biomarkers provide real-time snapshots of disease status with significant prognostic value, highlighting that ctDNA positivity after neoadjuvant therapy correlates with worse outcomes. Their discussion explores c...
|
- Details
- Sam Chang speaks with Sarah Psutka about an expanded access program for cretostimogene (CG0070) in BCG-unresponsive non-muscle invasive bladder cancer. Dr. Psutka explains that this oncolytic immunotherapy works by selectively replicating in cancer cells with RB pathway alterations, creating a dual mechanism that both kills tumor cells directly and triggers immune responses. The expanded access pr...
|
- Details
- Ashish Kamat speaks with Roberto Contieri about active surveillance for low-risk non-muscle invasive bladder cancer and novel approaches to patient selection. Dr. Contieri describes Humanitas Hospital's active surveillance protocol for patients with recurrent low-grade Ta tumors, highlighting that while 90% of patients who exit surveillance still have low-grade or benign pathology, approximately 1...
|
- Details
- Sam Chang hosts Yair Lotan to discuss non-coding RNA as a predictor of bladder cancer subtypes. Dr. Lotan describes a multicenter retrospective analysis of 230 cystectomy patients without neoadjuvant chemotherapy, focusing on identifying favorable subgroups within luminal tumors. His team found that specific non-coding RNA patterns within the luminal subtype correlate with less upstaging and bette...
|
